Pharma firm Lupin has received approval from the US health regulator to market its Desoximetasone ointment, used for providing relief from inflammation and itching in a skin disease.
The company has received final approval to market its Desoximetasone ointment USP, 0.05 per cent from the United States Food & Drug Administration (USFDA), Lupin said in a filing to BSE.
The product filing is from the company's Pithampur manufacturing facility, it added.
The Mumbai-based company's product is the generic version of Taro Pharms North's Topicort ointment in the same strength.
As per IMS, MAT September 2016 sales data, Topicort had US sales of USD 12.1 million, Lupin said.
The ointment is "indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses," it added.
The Lupin Ltd stock was trading marginally up at Rs 1,493 in the afternoon on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
